Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial | Cardiothoracic Surgery | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Murphy  GJ, Reeves  BC, Rogers  CA, Rizvi  SI, Culliford  L, Angelini  GD.  Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery.  Circulation. 2007;116(22):2544-2552. doi:10.1161/CIRCULATIONAHA.107.698977PubMedGoogle ScholarCrossref
2.
Faraoni  D, Willems  A, Savan  V, Demanet  H, De Ville  A, Van der Linden  P.  Plasma fibrinogen concentration is correlated with postoperative blood loss in children undergoing cardiac surgery: a retrospective review.  Eur J Anaesthesiol. 2014;31(6):317-326. doi:10.1097/EJA.0000000000000043PubMedGoogle ScholarCrossref
3.
Karkouti  K, Callum  J, Crowther  MA,  et al.  The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study.  Anesth Analg. 2013;117(1):14-22. doi:10.1213/ANE.0b013e318292efa4PubMedGoogle ScholarCrossref
4.
Spahn  DR, Bouillon  B, Cerny  V,  et al.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.  Crit Care. 2019;23(1):98. doi:10.1186/s13054-019-2347-3PubMedGoogle ScholarCrossref
5.
Boer  C, Meesters  MI, Milojevic  M,  et al; Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA).  2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.  J Cardiothorac Vasc Anesth. 2018;32(1):88-120. doi:10.1053/j.jvca.2017.06.026PubMedGoogle ScholarCrossref
6.
Callum  JL, Karkouti  K, Lin  Y.  Cryoprecipitate: the current state of knowledge.  Transfus Med Rev. 2009;23(3):177-188. doi:10.1016/j.tmrv.2009.03.001PubMedGoogle ScholarCrossref
7.
Dunbar  NM, Olson  NJ, Szczepiorkowski  ZM,  et al.  Blood component transfusion and wastage rates in the setting of massive transfusion in three regional trauma centers.  Transfusion. 2017;57(1):45-52. doi:10.1111/trf.13880PubMedGoogle ScholarCrossref
8.
Yazer  MH, Dunbar  NM, Cohn  C,  et al; Biomedical Excellence for Safer Transfusion (BEST) Collaborative.  Blood product transfusion and wastage rates in obstetric hemorrhage.  Transfusion. 2018;58(6):1408-1413. doi:10.1111/trf.14571PubMedGoogle ScholarCrossref
9.
Novak  A, Stanworth  SJ, Curry  N.  Do we still need cryoprecipitate? cryoprecipitate and fibrinogen concentrate as treatments for major hemorrhage—how do they compare?  Expert Rev Hematol. 2018;11(5):351-360. doi:10.1080/17474086.2018.1458610PubMedGoogle ScholarCrossref
10.
Jensen  NH, Stensballe  J, Afshari  A.  Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review.  Acta Anaesthesiol Scand. 2016;60(8):1033-1042. doi:10.1111/aas.12734PubMedGoogle ScholarCrossref
11.
Li  JY, Gong  J, Zhu  F,  et al.  Fibrinogen concentrate in cardiovascular surgery: a meta-analysis of randomized controlled trials.  Anesth Analg. 2018;127(3):612-621. doi:10.1213/ANE.0000000000003508PubMedGoogle ScholarCrossref
12.
Karkouti  K, Callum  J, Rao  V,  et al.  Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial.  BMJ Open. 2018;8(4):e020741. doi:10.1136/bmjopen-2017-020741PubMedGoogle Scholar
13.
Canadian Institutes of Health Research. Introducing TCPS 2 (2018)—Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Government of Canada website. http://www.pre.ethics.gc.ca/eng/nr-cp_2019-06-05.html. Published August 15, 2019. Accessed October 8, 2019.
14.
Erdoes  G, Gerster  G, Colucci  G, Kaiser  H, Alberio  L, Eberle  B.  Prediction of post-weaning fibrinogen status during cardiopulmonary bypass: an observational study in 110 patients.  PLoS One. 2015;10(5):e0126692. doi:10.1371/journal.pone.0126692PubMedGoogle Scholar
15.
Mace  H, Lightfoot  N, McCluskey  S,  et al.  Validity of thromboelastometry for rapid assessment of fibrinogen levels in heparinized samples during cardiac surgery: a retrospective, single-center, observational study.  J Cardiothorac Vasc Anesth. 2016;30(1):90-95. doi:10.1053/j.jvca.2015.04.030PubMedGoogle ScholarCrossref
16.
Bilecen  S, de Groot  JA, Kalkman  CJ,  et al.  Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: a randomized clinical trial.  JAMA. 2017;317(7):738-747. doi:10.1001/jama.2016.21037PubMedGoogle ScholarCrossref
17.
Nascimento  B, Callum  J, Tien  H,  et al.  Fibrinogen in the initial Resuscitation of Severe Trauma (FiiRST): a randomized feasibility trial.  Br J Anaesth. 2016;117(6):775-782. doi:10.1093/bja/aew343PubMedGoogle ScholarCrossref
18.
Winearls  J, Wullschleger  M, Wake  E,  et al.  Fibrinogen Early In Severe Trauma studY (FEISTY): study protocol for a randomised controlled trial.  Trials. 2017;18(1):241. doi:10.1186/s13063-017-1980-xPubMedGoogle ScholarCrossref
19.
Galas  FR, de Almeida  JP, Fukushima  JT,  et al.  Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial.  J Thorac Cardiovasc Surg. 2014;148(4):1647-1655. doi:10.1016/j.jtcvs.2014.04.029PubMedGoogle ScholarCrossref
20.
Green  L, Bolton-Maggs  P, Beattie  C,  et al.  British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding.  Br J Haematol. 2018;181(1):54-67. doi:10.1111/bjh.15167PubMedGoogle ScholarCrossref
21.
Callum  JL, Pinkerton  PH, Lima  A,  et al.  Bloody Easy 4: Blood Transfusions, Blood Alternatives and Transfusion Reaction. 4th ed. Toronto, Ontario, Canada: Ontario Regional Blood Coordinating Network; 2016.
22.
Dyke  C, Aronson  S, Dietrich  W,  et al.  Universal definition of perioperative bleeding in adult cardiac surgery.  J Thorac Cardiovasc Surg. 2014;147(5):1458-1463. doi:10.1016/j.jtcvs.2013.10.070PubMedGoogle ScholarCrossref
23.
Karkouti  K, Callum  J, Wijeysundera  DN,  et al; TACS Investigators.  Point-of-care hemostatic testing in cardiac surgery: a stepped-wedge clustered randomized controlled trial.  Circulation. 2016;134(16):1152-1162. doi:10.1161/CIRCULATIONAHA.116.023956PubMedGoogle ScholarCrossref
24.
Fleming  TR, Harrington  DP, O’Brien  PC.  Designs for group sequential tests.  Control Clin Trials. 1984;5(4):348-361. doi:10.1016/S0197-2456(84)80014-8PubMedGoogle ScholarCrossref
25.
Ahmed  S, Harrity  C, Johnson  S,  et al.  The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage—an observational study.  Transfus Med. 2012;22(5):344-349. doi:10.1111/j.1365-3148.2012.01178.xPubMedGoogle ScholarCrossref
26.
Theodoulou  A, Berryman  J, Nathwani  A, Scully  M.  Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenaemia.  Transfus Apher Sci. 2012;46(2):159-162. doi:10.1016/j.transci.2011.11.005PubMedGoogle ScholarCrossref
27.
Yang  L, Vuylsteke  A, Gerrard  C, Besser  M, Baglin  T.  Postoperative fibrinogen level is associated with postoperative bleeding following cardiothoracic surgery and the effect of fibrinogen replacement therapy remains uncertain.  J Thromb Haemost. 2013;11(8):1519-1526. doi:10.1111/jth.12304PubMedGoogle ScholarCrossref
28.
Leach Bennett  J, Blajchman  MA, Delage  G, Fearon  M, Devine  D.  Proceedings of a consensus conference: risk-based decision making for blood safety.  Transfus Med Rev. 2011;25(4):267-292. doi:10.1016/j.tmrv.2011.05.002PubMedGoogle ScholarCrossref
29.
Stramer  SL, Hollinger  FB, Katz  LM,  et al.  Emerging infectious disease agents and their potential threat to transfusion safety.  Transfusion. 2009;49(suppl 2):1S-29S. doi:10.1111/j.1537-2995.2009.02279.xPubMedGoogle ScholarCrossref
30.
Kleinman  S, Cameron  C, Custer  B,  et al.  Modeling the risk of an emerging pathogen entering the Canadian blood supply.  Transfusion. 2010;50(12):2592-2606. doi:10.1111/j.1537-2995.2010.02724.xPubMedGoogle ScholarCrossref
31.
Okerberg  CK, Williams  LA  III, Kilgore  ML,  et al.  Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients—an economic evaluation.  Vox Sang. 2016;111(3):292-298. doi:10.1111/vox.12417PubMedGoogle ScholarCrossref
32.
McQuilten  ZK, Bailey  M, Cameron  PA,  et al.  Fibrinogen concentration and use of fibrinogen supplementation with cryoprecipitate in patients with critical bleeding receiving massive transfusion: a bi-national cohort study.  Br J Haematol. 2017;179(1):131-141. doi:10.1111/bjh.14804PubMedGoogle ScholarCrossref
33.
McQuilten  ZK, Wood  EM, Bailey  M, Cameron  PA, Cooper  DJ.  Fibrinogen is an independent predictor of mortality in major trauma patients: a five-year statewide cohort study.  Injury. 2017;48(5):1074-1081. doi:10.1016/j.injury.2016.11.021PubMedGoogle ScholarCrossref
34.
Gillissen  A, van den Akker  T, Caram-Deelder  C,  et al; TeMpOH-1 Study Group.  Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study.  Blood Adv. 2018;2(19):2433-2442.PubMedGoogle ScholarCrossref
Original Investigation
October 21, 2019

Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial

Author Affiliations
  • 1Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  • 2Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada
  • 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
  • 4Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
  • 5Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada
  • 6Interdepartmental Division of Critical Care, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 7Sunnybrook Research Institute, Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  • 8Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
  • 9Department of Medicine, McMaster University, Hamilton, Ontario, Canada
  • 10University Health Network, Division of Cardiovascular Surgery, Toronto General Hospital, Toronto, Ontario, Canada
  • 11University of Toronto, Toronto, Ontario, Canada
  • 12Department of Biostatistics, ERGOMED CDS GmbH, Cologne, Germany
  • 13Department of Anesthesia and Pain Management, Sinai Health System, Women’s College Hospital, University Health Network, Toronto, Ontario, Canada
  • 14Department of Anesthesiology, Pharmacology and Therapeutics; University of British Columbia, Vancouver, Canada
  • 15Royal Columbian Hospital, Vancouver, British Columbia, Canada
  • 16Anesthesiology Department, Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Québec City, Québec, Canada
  • 17Departments of Anesthesiology, Perioperative and Pain Medicine, and Surgery, University of Manitoba, Winnipeg, Canada
  • 18Department of Anesthesia and Perioperative Medicine, Western University, London, Ontario, Canada
  • 19St Michael’s Hospital, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
  • 20Department of Anesthesiology, Montréal Heart Institute, Université de Montréal, Montréal, Québec, Canada
  • 21Department of Anesthesiology and Perioperative Medicine; Kingston General Hospital, Queen’s University, Kingston, Ontario, Canada
  • 22Department of Pathology and Molecular Medicine, Kingston Health Science Center, Queen’s University, Kingston, Ontario, Canada
  • 23Department of Anesthesiology; Hamilton Health Sciences Corporation, McMaster University, Hamilton, Ontario, Canada
  • 24University of Ottawa Heart Institute, Division of Cardiac Anesthesiology and Critical Care, Department of Anesthesia and Pain Medicine, University of Ottawa School of Epidemiology and Public Health, Ottawa, Ontario, Canada
  • 25Cardiac Surgery, Royal Columbian Hospital, University of British Columbia, Vancouver, Canada
  • 26McMaster Centre for Transfusion Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
  • 27Department of Anesthesia and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
JAMA. 2019;322(20):1966-1976. doi:10.1001/jama.2019.17312
Key Points

Question  Is fibrinogen concentrate noninferior to cryoprecipitate for treatment of bleeding related to acquired hypofibrinogenemia in cardiac surgery?

Findings  In this randomized trial of 735 adult patients who underwent cardiac surgery and developed clinically significant bleeding and hypofibrinogenemia post cardiopulmonary bypass, the mean number of blood components transfused within 24 hours post bypass was 16.3 units in the fibrinogen concentrate group and 17.0 units in the cryoprecipitate group; ratio of the mean number of units transfused was 0.96, which met the prespecified noninferiority margin ratio of less than 1.2.

Meaning  For management of cardiac surgery–associated bleeding related to acquired hypofibrinogenemia, fibrinogen concentrate may be considered for fibrinogen replacement.

Abstract

Importance  Excessive bleeding is a common complication of cardiac surgery. An important cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which guidelines recommend fibrinogen replacement with cryoprecipitate or fibrinogen concentrate. The 2 products have important differences, but comparative clinical data are lacking.

Objective  To determine if fibrinogen concentrate is noninferior to cryoprecipitate for treatment of bleeding related to hypofibrinogenemia after cardiac surgery.

Design, Setting, and Participants  Randomized clinical trial at 11 Canadian hospitals enrolling adult patients experiencing clinically significant bleeding and hypofibrinogenemia after cardiac surgery (from February 10, 2017, to November 1, 2018). Final 28-day follow-up visit was completed on November 28, 2018.

Interventions  Fibrinogen concentrate (4 g; n = 415) or cryoprecipitate (10 units; n = 412) for each ordered dose within 24 hours after cardiopulmonary bypass.

Main Outcomes and Measures  Primary outcome was blood components (red blood cells, platelets, plasma) administered during 24 hours post bypass. A 2-sample, 1-sided test for the ratio of the mean number of units was conducted to evaluate noninferiority (threshold for noninferiority ratio, <1.2).

Results  Of 827 randomized patients, 735 (372 fibrinogen concentrate, 363 cryoprecipitate) were treated and included in the primary analysis (median age, 64 [interquartile range, 53-72] years; 30% women; 72% underwent complex operations; 95% moderate to severe bleeding; and pretreatment fibrinogen level, 1.6 [interquartile range, 1.3-1.9] g/L). The trial met the a priori stopping criterion for noninferiority at the interim analysis after 827 of planned 1200 patients were randomized. Mean 24-hour postbypass allogeneic transfusions were 16.3 (95% CI, 14.9 to 17.8) units in the fibrinogen concentrate group and 17.0 (95% CI, 15.6 to 18.6) units in the cryoprecipitate group (ratio, 0.96 [1-sided 97.5% CI, −∞ to 1.09; P < .001 for noninferiority] [2-sided 95% CI, 0.84 to 1.09; P = .50 for superiority]). Thromboembolic events occurred in 26 patients (7.0%) in the fibrinogen concentrate group and 35 patients (9.6%) in the cryoprecipitate group.

Conclusions and Relevance  In patients undergoing cardiac surgery who develop clinically significant bleeding and hypofibrinogenemia after cardiopulmonary bypass, fibrinogen concentrate is noninferior to cryoprecipitate with regard to number of blood components transfused in a 24-hour period post bypass. Use of fibrinogen concentrate may be considered for management of bleeding in patients with acquired hypofibrinogenemia in cardiac surgery.

Trial Registration  ClinicalTrials.gov Identifier: NCT03037424

×